Fezolinetant for Vasomotor Symptoms in Menopause

Menopausal vasomotor symptoms occur in about 80% of women and have a significant impact on quality of life. Hormone replacement therapy works well; however, it is often underused. Join host, Geoff Wall, as he evaluates Fezolinetant, a new medication to treat 'hot flashes.'
The GameChanger
HRT is vastly underused in menopausal women. Gabapentin and SNRIs may help with some vasomotor symptoms. Fezolinetant is effective for hot flashes and seems to be well tolerated.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Lederman S, Ottery FD, Cano A, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023 Apr 1;401(10382):1091-1102. doi: 10.1016/S0140-6736(23)00085-5. Epub 2023 Mar 13. PMID: 36924778.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00085-5/fulltext

Pharmacist Members, REDEEM YOUR CPE HERE!

Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information

Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Discuss the pros and cons of hormone replacement therapy in women with vasomotor symptoms.
2. Discuss the role of fezolinetant for treatment of vasomotor symptoms.
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-365-H01-P
Initial release date: 11/27/2023
Expiration date: 11/27/2024
Additional CPE details can be found here.

Follow CEimpact on Social Media:
LinkedIn
Instagram